Lead (Pb)

Overview

Uncommon but potentially life-threatening. Often a chronic exposure.

Toxic mechanism

Competes with Ca or Zn to bind with enzymes/proteins (often via -SH groups). Interferes with cell membrane integrity & causes demyelination, the steroid synthesis, neurotransmitters.

Toxicokinetics

Abs through skin, inhalation or ingestion (esp prox small bowel, active transport with Fe^{2+}/Ca^{2+} , so \uparrow in Fe/Ca def, high fat diet, \uparrow acidity). Children abs 2-3x orally>adults. 3 compartment model: blood (<5% [99% in RBCs], $T_{\frac{1}{2}}$ =30d[child 10m]) \leftrightarrow soft tissue (liver, kidney, marrow & brain, $T_{\frac{1}{2}}$ =1-2m) \leftrightarrow bone(95% [70% child], $T_{\frac{1}{2}}$ up to 10y). Min renal excretion w/o chelation. Crosses placenta.

Clinical features

Acute: metallic taste, abdo pain, N&V, black diarrhoea, haemolytic anaemia & hepatitis, renal impairment, lethargy, myalgia. Cerebral oedema, encephalopathy, seizures & coma. *Chronic:* vague GI (anorexia, constipation, abdo pain) & CNS (headache, impaired conc/co-ord) symptoms, ↓wt, motor peripheral neuropathy, blue gum margins, renal fn, HT, subfertility, ↓IQ.

Investigations

Screening: ECG, paracetamol, BSL

Specific: Whole blood lead level, FBC, UEC, LFT, zinc protoporphyrin (surrogate measure of total body lead burden), blood film (basophilic stippling), AXR, limb XR (metaphyseal bands of arrested growth – "lead lines", nerve conduction/psychomotor studies), endoscopy

Lead level	Effects
≤10µg/dL (0.48µmol/L)	Minor dose-dependent JIQ in children
>10µg/dL (0.48µmol/L)	Subtle developmental, learning, motor & intellectual abnormalities in children
>30µg/dL (1.4µmol/L)	Non-specific symptoms, peripheral neuropathies, renal & fertility problems
>100µg/dL (4.8µmol/L)	Severe GI symptoms, encephalopathy, seizures & coma

Risk assessment

Acute severe OD \rightarrow encephalopathy, cerebral oedema & death. Chronically \rightarrow vague multi-organ disorder with GI, CNS sequelae. Teratogenic. Impairs child intellectual development.

Management

Resus: Rarely req. Mannitol & dexamethasone if cerebral oedema.

Supportive Care: Investigate /correct iron/zinc deficiency + hypocalcaemia Decontamination: Remove source/FB. Wash skin if dermal exposure. Ingested FB removed endoscopically/flushed with oral high residue diet+PEG or WBI. Peri-jt/CSF shrapnel. Enhanced Elimination: N/A.

Antidote: Chelation - IV/IM sodium calcium edetate if acute encephalopathy or BLL>100 μ g/dL (child 70 μ g/dL) or PO succimer if other symptoms or BLL>60 μ g/dL (child >45 μ g/dL). Prevention: \downarrow Re-exposure (seek & remove lead sources-see below)

Disposition

Depends on severity.

Notes

Sources: old houses with lead water pipes & lead paint, petrol, occupations (e.g. smelting, battery manufacture, solder), scrapping, traditional remedies, cosmetics, soil (pica), industrial & car emissions, or occasionally foreign bodies (lead weights).